亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Continuous intravenous tirofiban can improve the 90-day functional outcome and decrease 90-day mortality without increasing bleeding risk in acute ischemic stroke patients treated by endovascular therapy: A meta-analysis

替罗非班 医学 改良兰金量表 优势比 随机对照试验 内科学 冲程(发动机) 脑出血 麻醉 外科 蛛网膜下腔出血 缺血 缺血性中风 心肌梗塞 机械工程 经皮冠状动脉介入治疗 工程类
作者
Aiwu Zhang,Nihong Wu,Xintong Liu,Tao Jiang
出处
期刊:Journal of Clinical Neuroscience [Elsevier]
卷期号:99: 109-116 被引量:7
标识
DOI:10.1016/j.jocn.2022.03.008
摘要

Background The role of continuous intravenous administration of tirofiban in endovascular therapy is still unclear. This meta-analysis aims to evaluate the 90-day functional prognosis in acute ischemic stroke patients (AIS) treated by endovascular treatment and intravenous administration of tirofiban. Methods We searched PubMed, Embase, and CENTRAL databases with the subject terms “tirofiban”, “brain ischemia”, and some related free words. Inclusion criteria were: (1) cohort study or randomized control trials; (2) AIS patients who received endovascular therapy; (3) the intervention or exposure was intravenous tirofiban monotherapy or combined with intra-arterial tirofiban; (4) containing data on modified Rankin Scale at 90 days and including at least one of the following indicators: mortality, symptomatic intracranial hemorrhage (sICH), intracranial hemorrhage (ICH), and recanalization. A summary odds ratio was calculated. Results Twelve eligible studies, consisting of 3268 AIS participants, were identified. There was a significant trend of favorable outcomes (measured by mRS at three months) in the tirofiban group (ORs = 1.36; 95% CI = 1.09–1.70). In addition, compared with the non-tirofiban group, intravenous tirofiban was significantly associated with decreased risk of 90-day mortality (ORs = 0.73; 95% CI:0.59–0.89) and increased recanalization rate (ORs = 1.50; 95% CI:1.08–2.09) but no significant difference in rates of sICH (ORs = 0.93; 95% CI = 0.70–1.24) or ICH (ORs = 0.84; 95% CI = 0.62–1.15). Conclusions Intravenous tirofiban appears to be safe and effective when used following intra-arterial tirofiban or as monotherapy in AIS patients treated by endovascular therapy, which can improve the 90-day functional outcome, decrease the 90-day mortality and increase the possibility of early recanalization without increasing rates of sICH and ICH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
21秒前
37秒前
Orange应助科研通管家采纳,获得10
45秒前
赘婿应助sunshineboy采纳,获得10
53秒前
1分钟前
曲夜白完成签到 ,获得积分10
1分钟前
1分钟前
桐桐应助蒲亚东采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
蒲亚东发布了新的文献求助10
1分钟前
drsherlock发布了新的文献求助30
1分钟前
sunshineboy发布了新的文献求助10
2分钟前
2分钟前
haha发布了新的文献求助10
2分钟前
2分钟前
生动的箴发布了新的文献求助10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
3分钟前
老石完成签到 ,获得积分10
3分钟前
刻苦小凝发布了新的文献求助10
3分钟前
3分钟前
宓函发布了新的文献求助10
3分钟前
波里舞完成签到 ,获得积分10
3分钟前
赘婿应助蒲亚东采纳,获得10
3分钟前
3分钟前
蒲亚东发布了新的文献求助10
3分钟前
英俊的铭应助nana2hao采纳,获得10
3分钟前
3分钟前
nana2hao发布了新的文献求助10
4分钟前
LiuJiateng应助抹茶芝麻糊糊采纳,获得10
4分钟前
4分钟前
4分钟前
4分钟前
彭于晏应助科研通管家采纳,获得10
4分钟前
英俊的铭应助科研通管家采纳,获得10
4分钟前
科研通AI6.2应助刻苦小凝采纳,获得10
4分钟前
爱学习的小李完成签到 ,获得积分10
5分钟前
早日毕业脱离苦海完成签到 ,获得积分10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Weaponeering, Fourth Edition – Two Volume SET 1000
First commercial application of ELCRES™ HTV150A film in Nichicon capacitors for AC-DC inverters: SABIC at PCIM Europe 1000
Handbook of pharmaceutical excipients, Ninth edition 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5996989
求助须知:如何正确求助?哪些是违规求助? 7472866
关于积分的说明 16081597
捐赠科研通 5140062
什么是DOI,文献DOI怎么找? 2756132
邀请新用户注册赠送积分活动 1730598
关于科研通互助平台的介绍 1629796